Denmark Has One of the Largest Rates of Generic Penetration In Europe.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c33470) has announced the addition of the Espicom Business Intelligence Ltd report: Denmark Generics Market Intelligence Report to their offering.

Depending on your viewpoint, generic drugs represent either

the future of the global pharmaceutical industry or an irritating drain on the revenues of R&D based companies. The sector continues to grow in importance, fuelled by the twin pressures of therapeutically significant products coming off patent and health provider demands for lower prices. Analysts in industry and commerce must have a clear understanding of the threats and opportunities in key markets worldwide.

Generics market reports are produced by a multi-lingual editorial team with over 25 years pharmaceutical market experience. And when that experience is combined with one of the best healthcare market databases around, and informed by direct access to over 1200 companies and organisations worldwide, you have unbeatable, reliable, qualified and enriched market analysis.

Topics Covered

EXECUTIVE SUMMARY

INTRODUCTION

Key Facts

BACKGROUND

Geographic

Political

Economic

DEMOGRAPHIC DATA

Population

Population by Region & Gender, 2005

Population by Age & Gender, 2005

Principal Demographic Indicators

Demographic Indicators, 2000-2004

Causes of Death

HEALTHCARE SYSTEM

Organisation

Expenditure

Healthcare Infrastructure

Hospitals

Hospitals by Type, 2002

Clinics

Outpatient Activity by Region, 2002

Outpatient Activity by Specialty, 2002

Medical Personnel

GENERIC PHARMACEUTICAL MARKET

In Context

Summary of the Danish Pharmaceutical Market, 2006

Number of Active Substances, Medicinal Products and Packs, on December 31st 1999-2004

Pharmaceutical Consumption at Pharmacy Purchasing Price, 2004 (DKr million)

Current size

Projections/Outlook

Projected Generic Market, 2006-2011 (US$ millions)

SWOT Analysis of the Danish Generic Pharmaceutical Market

Regulatory Landscape

Patent Protection & Intellectual Property Rights

Supplementary Protection Certificates

Pricing and Reimbursement

Pricing

Generic substitution

Reimbursement

Relationship Between Annual Consumption and Pharmaceutical Reimbursement, 2005

Domestic Production

Industriforeningen for Generiske Laegemidler (IGL)

1A-Farma

Alternova

Copyfarm

Merck NM

PharmaCoDane

Sandoz

DIRECTORY

Trade Associations

Manufacturers

Summary

Denmark has one of Europe's highest levels of generic penetration, but with a population of only around 5.4 million is sometimes overlooked in comparison with Germany or the UK. The healthcare system is extensive and generally well-funded, but government cost pressures have led to the tightening of the reimbursement regime in the past year. The country has long been one of Europe's main destinations for parallel trade medicines, although downward pressure on prices may change this situation in the longer term.

The country's health indicators are relatively poor for such a developed country, a situation attributed to poor diet, lack of exercise, and high levels of alcohol/tobacco consumption.

The country has little domestic generic manufacturing, but is receptive to imported drugs from elsewhere in the EU. Multinationals present in the market include Actavis, ratiopharm and Sandoz.

This in-depth report provides a wide-ranging examination of the generic pharmaceuticals market, including the operating environment, current market size, future prospects and five-year market projections.

For more information visit http://www.researchandmarkets.com/reports/c33470